CER Daily Newsfeed

Novo Nordisk’s CagriSema Beaten by Lilly’s Zepbound in Head-to-Head Obesity Trial

(2/23, Elizabeth Cairns, Endpoints News) reports “...Patients in the REDEFINE 4 trial who were taking CagriSema lost 20.2% of their weight after 84 weeks. Those taking Lilly’s drug lost 23.6%. This was when the data were analyzed using the treatment-regimen estimand, which counts missing data as treatment failures. According to a different analysis that treated all patients as adherent to treatment, the weight loss figures were 23% with CagriSema and 25.5% with Zepbound.” Subscription Required

Balancing Safety, Efficacy, and Patient Preference in Biologic Selection for Inflammatory Disease

(2/23, Pearl Steinzor, The American Journal of Managed Care) comments “...Cross-trial comparisons present additional challenges. Without head-to-head studies, indirect comparisons between therapies can be misleading due to differences in study populations and methodologies. Comparative effectiveness research is therefore highly valued to guide formulary decisions and managed care policy.” Full

Innovation Stagnation: The Plight Of Dialysis Patients In The US

(2/20, Suzanne Watnick, Health Affairs Forefront) comments “...CMS could, for example, consider broader value-based payment models to incentivize care for people throughout their lives with chronic kidney disease, including kidney failure and kidney transplantation. CMS could also provide financial incentives to facilities that actively participate in national research registries or pilot new modalities. Regulatory reform to allow pragmatic comparative effectiveness research within facilities could substantively benefit patients.” Full